Design Therapeutics(DSGN) - 2024 Q2 - Quarterly Results

Financial Performance - Research and development (R&D) expenses for Q2 2024 were $10.5 million, a decrease from$17.1 million in Q2 2023[4] - General and administrative (G&A) expenses for Q2 2024 were $4.5 million, down from$5.5 million in Q2 2023[4] - The net loss for Q2 2024 was $11.8 million, compared to a net loss of$19.9 million in Q2 2023[4] - Total operating expenses for Q2 2024 were $15.0 million, down from$22.6 million in Q2 2023[8] Cash Position - Cash, cash equivalents, and marketable securities totaled $261.0 million as of June 30, 2024, expected to fund operations into 2029[4] Clinical Development - The company is on track to start patient trials for DT-216P2 in Friedreich Ataxia (FA) in 2025[3] - DT-168 for Fuchs Endothelial Corneal Dystrophy (FECD) is advancing toward Phase 1 development later this year, with 200 patients to be enrolled in an observational study[3] - The company aims to complete GLP studies for DT-216P2 by year-end 2024[3] - Design Therapeutics is progressing preclinical programs for Huntington's Disease (HD) and Myotonic Dystrophy Type-1 (DM1) in anticipation of future IND submissions[3] Share Information - The weighted-average shares of common stock outstanding for Q2 2024 were approximately 56.6 million, compared to 55.9 million in Q2 2023[8]